This website uses cookies to enhance your browsing experience, improve site performance, and gather analytics. By selecting 'Accept,' you consent to these cookies as described in our Privacy Policy.

Study to Evaluate the PK of IV and PO Omadacycline in Children and Adolescents With Suspected or Confirmed Bacterial Infections

Sponsored by Paratek Pharmaceuticals Inc

About this trial

Last updated 2 years ago

Study ID

PTK0796-PEDPK-20110

Status

Recruiting

Type

Interventional

Phase

Phase 1

Placebo

No

Accepting

18-75 Years
8 to 17 Years
All
All

Not accepting

Not accepting
Healthy Volunteers

Trial Timing

Ended 2 years ago

What is this trial about?

The purpose of this study is to evaluate the pharmacokinetics of a single dose of intravenous or oral omadacycline in children and adolescents with suspected or confirmed bacterial infections.

What are the participation requirements?

Yes

Inclusion Criteria

- Male or female subjects, age 8 to < 18 (inclusive) who have written and signed parental/legal authorized representative (LAR) informed consent and pediatric assent.

- Currently hospitalized with a suspected or confirmed bacterial infection and receiving or planned to receive systemic antibiotic therapy other than omadacycline.

- Weight within the 5th and 95th percentile for age and sex.

- Subjects must not be pregnant or nursing at the time of enrollment, and must agree to use a highly effective birth control method during the study

No

Exclusion Criteria

- Evidence of a medical condition that may pose a safety risk or impair study participation.

- Confirmed or suspected SARS-CoV-2 infection.

- Has a history of hypersensitivity or allergic reaction to any tetracycline antibiotic.

- Has received an investigational drug within the past 30 days.

Locations

Location

Status

Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting